ABCL AbCellera Biologics Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Hayden Michael R	2. Issuer Name and Ticker or Trading Symbol AbCellera Biologics Inc. [ ABCL ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 9/13/2021
(Street) VANCOUVER, A1  (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	9/13/2021		M		270000	A	$17.73	1273397 (1)	I	See footnote
Common Shares								118245	I	By spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	$0.32 (2)	9/13/2021		M		270000		(3)	9/11/2029	Common Shares	270000	$0.00	270000 (1)	I	See footnote

Explanation of Responses:
(1)	These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
(2)	Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.32:USD $1.00 for September 11, 2019 as set forth on Bloomberg.
(3)	The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on September 11, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Hayden Michael R C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER, A1	X

Signatures
/s/ Tryn Stimart, attorney-in-fact		9/15/2021
**Signature of Reporting Person		Date